Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | ESRRG | P62508 | 2/20 | 0.55 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9122265 | 1.00 | LTA4H (0.77) | LTA4HALDH1A1KDM4ESIGMAR1MAPT | |
| SCHEMBL5455464 | 0.94 | LTA4H (0.69) | LTA4HALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9097701 | 0.91 | LTA4H (0.66) | LTA4HALDH1A1KDM4ESIGMAR1MAPT | |
| SCHEMBL22266156 | 0.90 | LTA4H (0.65) | LTA4HALDH1A1KDM4ESIGMAR1MAPT | |
| SCHEMBL5752269 | 0.90 | LTA4H (0.64) | LTA4HALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL22266155 | 0.88 | LTA4H (0.62) | LTA4H | |
| SCHEMBL22151427 | 0.88 | LTA4H (0.79) | LTA4HALDH1A1KDM4EESRRGSMN1; SMN2 | |
| SCHEMBL7142372 | 0.88 | LTA4H (1.00) | LTA4H | |
| SCHEMBL11874817 | 0.86 | LTA4H (0.68) | LTA4HALDH1A1KDM4ESIGMAR1MAPT | |
| SCHEMBL5331925 | 0.85 | HRH3 (0.67) | LTA4HALDH1A1KDM4ESIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655518-A | Isatin derivative and preparation method and application thereof | 东南大学 | 2023-08-29 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| CN-116655518-A | Isatin derivative and preparation method and application thereof | 东南大学 | 2023-08-29 | — | — | CN | disclosed |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10113049-B2 | Thermoplastic resin composition | NIPPON NYUKAZAI CO., LTD. (JP) | 2018-10-30 | — | — | US | disclosed |
| EP-2744775-B1 | BAX AGONIST, COMPOSITIONS, AND METHODS RELATED THERETO | UNIV EMORY (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9730944-B2 | Antiviral activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | disclosed |
| EP-0859607-A4 | GUANIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0859607-A1 | GUANIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-08-26 | — | — | EP | disclosed |
| US-5792769-A | POTENT ANTICOAGULANT, ANTIINFLAMMATORY AGENT; TREATMENT/PROPHYLAXIS OF RESPIRATORY SYSTEM DISORDERS, VASCULAR SYSTEM DISORDERS, ANTITUMOR AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| WO-1997011693-A1 | GUANIDINO PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1997-04-03 | — | — | WO | disclosed |
| US-5395934-A | Antiarrhythmia agents and cardiovascular disorders | EGIS GYOGYSZERGYAR (HU) | 1995-03-07 | — | — | US | disclosed |
| US-4582833-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| US-4562189-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1985-12-31 | — | — | US | disclosed |
| US-4259334-A | Piperazines and therapeutic utility | LAROCHE NAVARRON S.A. (FR) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | LTA4H 145/4885ALDH1A1 1006/4885KDM4E 2405/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | LTA4H 3562/4885ALDH1A1 2833/4885KDM4E 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.